Targeting Wnt5A signaling to improve treatment for advanced prostate cancer
Official title: Therapeutic targeting Wnt5A signaling for advanced prostate cancer
Funded at University of California at Davis · NIH-10986078 · Data updated 2026-11-12
This study is looking at how a specific signaling process called Wnt5A affects advanced prostate cancer that doesn't respond to common treatments, with the goal of finding new ways to make these treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | December 1, 2020 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $367,236 |
| NIH project number | 5R01CA250082-05 |
| Project ID | NIH-10986078 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced prostate cancer who have developed resistance to enzalutamide or abiraterone.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet received treatment with enzalutamide or abiraterone may not benefit from this research.
What this research studies
This research investigates the role of Wnt5A signaling in advanced prostate cancer, particularly in cases resistant to common treatments like enzalutamide and abiraterone. The study aims to understand how Wnt5A contributes to drug resistance and to develop new strategies to inhibit this signaling pathway. By exploring two novel approaches to target Wnt5A, the research seeks to enhance the effectiveness of existing therapies and potentially resensitize cancer cells to treatment. Patients may benefit from insights that could lead to improved therapeutic options for advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could provide new treatment strategies that enhance the effectiveness of current therapies for advanced prostate cancer.
How similar studies have gone: Previous studies have shown promising results in targeting Wnt signaling pathways in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Gao, Allen C. — University of California at Davis
- Study coordinator: Gao, Allen C.
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.